We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $881M
1-Year Est. Return 160.77%
This Fund
S&P 500
This Quarter Est. Return
+1.09%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$950M
AUM Growth
-$134M
Cap. Flow
+$674K
Cap. Flow %
0.07%
Top 10 Hldgs %
97.71%
Holding
16
New
–
Increased
2
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$7.55M
2
KRRO icon
Korro Bio
KRRO
+$987K

Top Sells

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$4.55M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$1.2M
3
XLO icon
Xilio Therapeutics
XLO
+$1.07M
4
KYMR icon
Kymera Therapeutics
KYMR
+$933K
5
SPRO icon
Spero Therapeutics
SPRO
+$109K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
1
Dyne Therapeutics
DYN
$3.37B
$283M 29.8%
8,020,136
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$9.85B
$160M 16.82%
5,350,422
-26,940
-0.5% -$933K
THRD
3
DELISTED
Third Harmonic Bio
THRD
$142M 14.93%
10,907,859
– –
IRON icon
4
Disc Medicine
IRON
$2.66B
$113M 11.91%
2,509,456
+222,223
+10% +$7.55M
DAWN
5
DELISTED
Day One Biopharmaceuticals
DAWN
$88.6M 9.33%
6,430,257
– –
KRRO icon
6
Korro Bio
KRRO
$174M
$38.5M 4.06%
1,137,149
+17,857
+2% +$987K
QTTB icon
7
Q32 Bio
QTTB
$323M
$37.6M 3.95%
2,092,106
– –
GBIO
8
DELISTED
Generation Bio
GBIO
$23.3M 2.46%
827,948
– –
VIGL
9
DELISTED
Vigil Neuroscience
VIGL
$23.3M 2.46%
5,836,874
– –
REPL icon
10
Replimune Group
REPL
$1.21B
$18.9M 1.99%
2,098,300
– –
IMA
11
ImageneBio Inc
IMA
$57M
$8.28M 0.87%
418,182
– –
TECX
12
Tectonic Therapeutic
TECX
$532M
$6.23M 0.66%
378,447
-1
-0% -$16
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.66B
$3.55M 0.37%
136,979
-50,000
-27% -$1.2M
JBIO
14
Jade Biosciences
JBIO
$1.09B
$2.99M 0.31%
51,407
-6,857
-12% -$4.55M
SPRO icon
15
Spero Therapeutics
SPRO
$65.2M
$696K 0.07%
535,336
-72,277
-12% -$109K
XLO icon
16
Xilio Therapeutics
XLO
$59.5M
– –
-70,922
Closed -$1.07M

Similar funds

AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
FSCM
Front Street Capital Management Missoula, Montana $881M AUM 86.5% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $882M AUM 62.77% 1-Year Est. Return
TAM
TCP Asset Management Columbus, Ohio $882M AUM 21.79% 1-Year Est. Return
FFG
Fiduciary Financial Group San Rafael, California $882M AUM 23.98% 1-Year Est. Return
MWA
Meridian Wealth Advisors Austin, Texas $880M AUM 30.15% 1-Year Est. Return
1IA
1834 Investment Advisors Milwaukee, Wisconsin $883M AUM 23.82% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $880M AUM 44.18% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Atlas Venture Life Science Advisors held 16 positions worth $950M, down 12% from $1.08B the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Atlas Venture Life Science Advisors's Q2 2024 filing shows 2 increased, 5 reduced and 1 closed positions. The largest sale was Jade Biosciences, an estimated $4.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors added most to Disc Medicine in Q2 2024, an estimated $7.55M increase.
  • Atlas Venture Life Science Advisors's biggest Q2 2024 reduction was Jade Biosciences, cutting an estimated $4.55M.
  • Atlas Venture Life Science Advisors fully exited Xilio Therapeutics in Q2 2024, selling an estimated $1.07M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 98% of its $950M portfolio in Q2 2024.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q2 2024.
  • Atlas Venture Life Science Advisors's portfolio value fell 12% quarter-over-quarter to $950M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.